Information  X 
Enter a valid email address

MJ Gleeson Plc (GLE)

  Print      Mail a friend       Annual reports

Thursday 05 December, 2019

MJ Gleeson Plc

Result of AGM

RNS Number : 8781V
MJ Gleeson PLC
05 December 2019
 

MJ GLEESON plc

Incorporated in England and Wales

Registration number: 09268016

LEI: 21380064K7N2W7FD6434

ISIN: GB00BRKD9Z53

 

 

 

MJ Gleeson plc

("the Company")

 

 

MJ Gleeson plc - AGM Results

 

The Company announces that all the resolutions put to the Annual General Meeting held at 11.30 a.m. on 5th December 2019 were passed on a show of hands.

 

The following table gives details of the proxy votes lodged with the Company's registrars as at 4 December 2019.

 

Resolution

Total Votes For *
(%)

Total Votes Against
(%)

Total Votes
Withheld

1.    To receive and adopt the Accounts for the year ended 30 June 2019 and the Directors' and Auditors' Reports thereon.

38,866.314 (100.0%)

5,623

(0.0%)

801

2.    To approve final dividend of 23p per ordinary share.

38,871,938 (100.0%)

0

(0.0%)

801

3.    To re-appoint Stefan Allanson as a Director.

36,205,655 (93.1%)

2,655,116

 (6.9%)

1,967

4.    To re-appoint Dermot Gleeson as a Director.

37,472,492 (96.4%)

1,399,445 (3.6%)

801

5.    To appoint James Thomson as a Director.

38,837,404 (99.9%)

34,534

(0.1%)

801

6.    To re-appoint James Ross Ancell as a Director.

37,241,160 (96.6%)

1,292,395 (3.4%)

339,183

7.    To re-appoint Christopher Mills as a Director.

31,683,104 (81.5%)

7,183,955 (18.5%)

5,679

8.    To re-appoint Colin Dearlove as a Director.

38,220,700 (98.3%)

651,237

(1.7%)

801

9.    To appoint Fiona Goldsmith as a Director.

38,854,264 (100.0%)

17,673

(0.0%)

801

10.  To appoint Andrew Coppel as a Director.

38,858,706 (100.0%)

13,232

(0.0%)

801

11.  To re-appoint PricewaterhouseCoopers LLP as Auditors.

38,859,597 (100.00%)

12,163

(0.0%)

979

12.  To authorise the Directors to determine Auditors' remuneration

38,867,228 (100.00%)

4,710

(0.0%)

801

13.  To approve the Directors' Remuneration Report.

38,213,708 (98.3%)

656,229

(1.7%)

2,801

14.  To approve the Directors' Remuneration Policy.

38,188,152 (98.2%)

681,785

(1.8%)

2,801

15.  To approve the purchase of land in Cumbriafrom HIPL.

32,410,006 (99.7%)

105,638

(0.3%)

6,357,094

16.  To authorise the Directors to allot shares in the Company pursuant to Section 551 of the Companies Act 2006.

38,831,660 (99.9%)

28,339

(0.1%)

12,740

17.  To disapply pre-emption rights in connection with a rights issue.

38,750,946 (99.7%)

113,875

(0.3%)

7,918

18.  To disapply pre-emption rights in connection with allotment of equity securities or sale of treasury shares.

38,754,663 (99.7%)

110,157

(0.3%)

7,918

19.  To authorise the Company to purchase its own shares under Section 701 of the Companies Act 2006.

38,855,357 (100.0%)

16,580

(0.0%)

801

20.  To authorise the Company to call General Meetings other than Annual General Meetings on not less than 14 clear days' notice.

38,719,142 (99.6%)

152,796

(0.4%)

801

* Includes discretionary votes

 

 

 

Notes:

 

(1)  A "vote withheld" is not a vote in law and is not counted in the total number of votes cast for or against a resolution.

 

(2)  Resolutions 1-16 were ordinary resolutions and resolutions 17-20 were special resolutions.

 

Copies of the special business resolutions passed at the Annual General Meeting will shortly be available for inspection via the Financial Services Authority's National Storage Mechanism in accordance with 9.6.2(R) of the Listing Rules

 

There were 55,309,014 ordinary shares of 2p each in issue on 5 December 2019.

 

Further information is available from:

 

MJ Gleeson plc

Stefan Allanson

Chief Financial Officer & Company Secretary

 

Tel: 01142 612900

 

5 December 2019

 

 

END


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGMMMGZKKVGLZM

a d v e r t i s e m e n t